Kezar Life Sciences, Inc. (KZR) Financial Analysis and Rating
Comparison Analysis Based on SEC Data
|Company Name||Kezar Life Sciences, Inc.|
|Industry (SIC)||2834 - Pharmaceutical Preparations|
|Assets as of 12/31/2022||$299,568 thousand|
|Fiscal Year End||December 31|
|Analyzed report||12/31/2020 (filed 3/11/2021)|
Financial Position and Performance
|Compared with 2020 industry ratios||Change during the year|
|Compared with all listed companies|
Financial Ratios Benchmarking
|Finanancial Ratio||Comparison of 2020 company ratios|
with industry ratios
(28 - Chemicals And Allied Products)
|with all listed companies|
|ROE (Return on equity), after tax||
|ROA (Return on assets)||
We have performed a comparative analysis of the balance sheet and income statement of Kezar Life Sciences, Inc. (hereafter – the "Company") for the year 2020 as submitted to the U.S. Securities and Exchange Commission (SEC). The primary business activity of the Company is "Pharmaceutical Preparations" (SIC code 2834). In the analysis, we have compared the key financial ratios of the Company with the average (median) values of those ratios calculated for the specific industry sector and for all companies. The averages are calculated using data from 2020 financial statements filed with the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics to the median, we have drawn a general conclusion about the quality of the company's financial condition. Calculations and summary conclusions are performed in a computerized manner using software and methodologies developed by ReadyRatios.
As a result of the analysis of the key financial ratios of the Company, we have established the following. The financial condition of Kezar Life Sciences, Inc. in 2020 is much better than the financial condition of half of all companies engaged in the activity "Pharmaceutical Preparations".
A similar result was obtained when comparing the financial performance of the Company with the average ratios of all companies. The financial position of Kezar Life Sciences, Inc. is better than that of most listed companies that submit financial statements to the U.S. Securities and Exchange Commission.
Financial Position and Performance History
More on Kezar Life Sciences, Inc.
|Company||USD ($), in Millions|
|Monopar Therapeutics Inc.||0||13|
|DICE Therapeutics, Inc.||0||594|
|Iterum Therapeutics plc||0||67|
|Moleculin Biotech, Inc.||0||57|
Financial Data Source and Analysis Principles
The above is a comparative analysis of the company's financial position and performance. The comparison is based on official financial statements filed with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) (about 10,000 largest publicly traded companies). The comparison is made using the eleven key financial ratios (see the table above). The company's financial ratios are compared with the median of the ratios for all companies and for companies in the same industry, as well as to the quartiles of these ratios. Each ratio value is assigned a score between -2 and +2 depending on its position relative to the quartiles (-2 – below the first quartile; -1 – between the first and the second quartile; +1 – between the second and the third quartile; +2 – above the third quartile; 0 – the ratio value deviates from the median by no more than 5% of the difference between the median and the quartile closest to the ratio value). To draw a conclusion from the analysis, the individual scores are weighted equally to produce an overall score ranging from -2 and +2.
|much better (+1 - +2incl)|
|better (from 0.11 to +1incl)|
|about the same (from -0.11incl to +0.11incl)|
|worse (from -1incl to -0.11)|
|much worse (from -2incl to -1)|
Change during the year is calculated by comparing the resulting score of financial position within the industry with the last year's (quarter's) score. The result of the comparison may be as follows:
|significantly improved (positive change of more than 1 point)|
|improved (positive change of less than 1 point)|
|unchanged (little or no change in score, no more than 0.11 points)|
|deteriorated (the score has decreased by less than 1 point during the year)|
|deteriorated significantly (the score has decreased by more than 1 point during the year)|
Please note that this analysis does not indicate that the company's financial position is good or bad, but rather describes it in comparison to other U.S. businesses. For a detailed financial analysis, please use "ReadyRatios Financial Analysis" - load the data into the program>>